首页 > 最新文献

Graefe’s Archive for Clinical and Experimental Ophthalmology最新文献

英文 中文
Efficacy of vitrectomy combined with and without cataract surgery for diabetic macular edema: one-year follow-up multi-center study in Japan. 玻璃体切除术联合或不联合白内障手术治疗糖尿病性黄斑水肿的疗效:日本一年随访的多中心研究。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-05-06 DOI: 10.1007/s00417-025-06845-2
Yutaka Yamada, Yoshihiro Takamura, Kazuma Saito, Akira Minamoto, Gaku Ishigooka, Takashi Koto, Yuki Nakano, Eiko Tsuiki, Hiroto Terasaki, Miho Shimizu, Masayo Kimura, Yoshinori Mitamura, Reio Sekine, Yutaro Mizusawa, Takao Hirano, Tomoyuki Oyama, Takeshi Iwase, Fumiaki Higashijima, Hisashi Matsubara, Masaru Inatani

Purpose: To evaluate the efficacy of vitrectomy, with and without cataract surgery, for diabetic macular edema (DME) in Japan.

Method: This retrospective study was conducted at 22 sites in Japan and enrolled patients who underwent vitrectomy either without (VIT group) or with (VIT + CS group) cataract surgery. Central retinal thickness (CRT) and best-corrected visual acuity (BCVA) were measured before surgery and at 1, 3, 6, and 12 months after surgery.

Results: A total of 722 patients with DME (482 in the VIT + CS group and 240 in the VIT group) were enrolled. CRT significantly decreased after 1 month and continued thereafter in both groups. BCVA significantly improved at 1 month in the VIT + CS group and at 6 months in the VIT group. In both groups, regardless of epiretinal membrane removal, CRT and BCVA significantly improved, with no additional benefit from concomitant internal limiting membrane peeling. The change in BCVA was significantly correlated with the change in CRT during 6 months postoperatively in all patients and in the VIT group. Patients with worse preoperative visual acuity had a higher likelihood of improved BCVA at 6 and 12 months after surgery. No significant difference in BCVA was observed before and after surgery in patients with a preoperative visual acuity of 20/40 or better. However, in patients with a visual acuity of 20/50 or worse, BCVA significantly improved 1 month after surgery.

Conclusion: Vitrectomy is anatomically and functionally effective for DME, and combined cataract surgery is beneficial in DME cases with cataracts. Patients with poor preoperative BCVA improved, while those with good vision maintained it. However, better preoperative vision increased the risk of postoperative deterioration, underscoring the need for careful evaluation of surgical indications.

Key messages: What is known In vitrectomy for diabetic macular edema (DME), DRCR.net showed that 13-31% of patients experience decreased vision despite reduced edema, leaving the efficacy of vitrectomy uncertain. What is new Our multicenter study demonstrated that vitrectomy with and without cataract surgery was effective in improving central retinal thickness and visual acuity in the patients with DME. Better preoperative visual acuity increased the risk of postoperative decline, and thus the need for careful evaluation of surgical indications.

目的:评价玻璃体切除术合并和不合并白内障手术治疗日本糖尿病性黄斑水肿(DME)的疗效。方法:本回顾性研究在日本的22个地点进行,并纳入了玻璃体切除术患者,包括不进行玻璃体切除术(VIT组)和白内障手术(VIT + CS组)。分别于术前、术后1、3、6、12个月测量视网膜中央厚度(CRT)和最佳矫正视力(BCVA)。结果:共纳入722例DME患者(VIT + CS组482例,VIT组240例)。两组患者1个月后CRT均显著降低,此后持续下降。VIT + CS组1个月和VIT组6个月时BCVA显著改善。在两组中,无论是否切除视网膜前膜,CRT和BCVA均有显著改善,同时伴有内限制膜剥离没有额外的益处。所有患者及VIT组术后6个月BCVA变化与CRT变化显著相关。术前视力较差的患者在术后6个月和12个月BCVA改善的可能性更高。术前视力在20/40及以上的患者手术前后BCVA无显著差异。然而,在视力为20/50或更差的患者中,BCVA在术后1个月显著改善。结论:玻璃体切除术在解剖和功能上是有效的,联合白内障手术对DME合并白内障是有益的。术前BCVA较差的患者BCVA改善,视力良好的患者BCVA维持。然而,术前良好的视力增加了术后恶化的风险,强调需要仔细评估手术指征。在玻璃体切除术治疗糖尿病黄斑水肿(DME)中,DRCR.net显示,13-31%的患者尽管水肿减轻,但视力下降,这使得玻璃体切除术的疗效不确定。我们的多中心研究表明,玻璃体切除术合并或不合并白内障手术对改善DME患者的中央视网膜厚度和视力都是有效的。术前视力较好会增加术后视力下降的风险,因此需要仔细评估手术指征。
{"title":"Efficacy of vitrectomy combined with and without cataract surgery for diabetic macular edema: one-year follow-up multi-center study in Japan.","authors":"Yutaka Yamada, Yoshihiro Takamura, Kazuma Saito, Akira Minamoto, Gaku Ishigooka, Takashi Koto, Yuki Nakano, Eiko Tsuiki, Hiroto Terasaki, Miho Shimizu, Masayo Kimura, Yoshinori Mitamura, Reio Sekine, Yutaro Mizusawa, Takao Hirano, Tomoyuki Oyama, Takeshi Iwase, Fumiaki Higashijima, Hisashi Matsubara, Masaru Inatani","doi":"10.1007/s00417-025-06845-2","DOIUrl":"10.1007/s00417-025-06845-2","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy of vitrectomy, with and without cataract surgery, for diabetic macular edema (DME) in Japan.</p><p><strong>Method: </strong>This retrospective study was conducted at 22 sites in Japan and enrolled patients who underwent vitrectomy either without (VIT group) or with (VIT + CS group) cataract surgery. Central retinal thickness (CRT) and best-corrected visual acuity (BCVA) were measured before surgery and at 1, 3, 6, and 12 months after surgery.</p><p><strong>Results: </strong>A total of 722 patients with DME (482 in the VIT + CS group and 240 in the VIT group) were enrolled. CRT significantly decreased after 1 month and continued thereafter in both groups. BCVA significantly improved at 1 month in the VIT + CS group and at 6 months in the VIT group. In both groups, regardless of epiretinal membrane removal, CRT and BCVA significantly improved, with no additional benefit from concomitant internal limiting membrane peeling. The change in BCVA was significantly correlated with the change in CRT during 6 months postoperatively in all patients and in the VIT group. Patients with worse preoperative visual acuity had a higher likelihood of improved BCVA at 6 and 12 months after surgery. No significant difference in BCVA was observed before and after surgery in patients with a preoperative visual acuity of 20/40 or better. However, in patients with a visual acuity of 20/50 or worse, BCVA significantly improved 1 month after surgery.</p><p><strong>Conclusion: </strong>Vitrectomy is anatomically and functionally effective for DME, and combined cataract surgery is beneficial in DME cases with cataracts. Patients with poor preoperative BCVA improved, while those with good vision maintained it. However, better preoperative vision increased the risk of postoperative deterioration, underscoring the need for careful evaluation of surgical indications.</p><p><strong>Key messages: </strong>What is known In vitrectomy for diabetic macular edema (DME), DRCR.net showed that 13-31% of patients experience decreased vision despite reduced edema, leaving the efficacy of vitrectomy uncertain. What is new Our multicenter study demonstrated that vitrectomy with and without cataract surgery was effective in improving central retinal thickness and visual acuity in the patients with DME. Better preoperative visual acuity increased the risk of postoperative decline, and thus the need for careful evaluation of surgical indications.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2651-2662"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intracellular dark endothelial spots: A new imaging biomarker for the development of bullous keratopathy after cataract surgery. 细胞内暗内皮斑点:白内障术后大疱性角膜病变发展的新成像生物标志物。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-09-01 Epub Date: 2025-04-29 DOI: 10.1007/s00417-025-06846-1
Taiyo Shijo, Yukari Yagi-Yaguchi, Osama Ibrahim, Hirotsugu Kasamatsu, Yurina Mori-Ogiwara, Daisuke Tomida, Hisashi Noma, Dogru Murat, Takefumi Yamaguchi

Purpose: Intracellular dark endothelial spots (IDES) on specular microscopy indicate corneal endothelial stress, and can be an imaging biomarker for subsequent endothelial cell density (ECD) loss after endothelial keratoplasty. This study evaluated the risk factors for the development of bullous keratopathy (BK) by comparing low ECD patients with or without IDES before cataract surgery.

Methods: This retrospective study included 106 consecutive patients who underwent cataract surgery with a preoperative ECD of less than 1000 cells/mm2. The patients were divided into 2 groups according to presence of IDES. The medical charts were retrospectively reviewed for preoperative central corneal thickness (CCT), ECD, anterior chamber depth (ACD), presence of IDES, presence of guttae, grade of nuclear sclerosis, intraoperative posterior capsule rupture (PCR) and development of BK after cataract surgery. The clinical factors were compared in patients with or without IDES and the risk factors for BK after cataract surgery were evaluated.

Results: The mean preoperative ECD was 687 ± 124 cells/mm2. IDES were observed in 41 eyes (38.7%). IDES were significantly more common in eyes with shallow ACD than in those with deep ACD (P = 0.033). Twenty-two eyes (20.8%) developed BK after cataract surgery. IDES were significantly associated with the development of BK (31.7%) compared to those without BK (13.9%, P = 0.03). CCT, nuclear sclerosis, PCR, and IDES were identified as significant risk factors for postoperative BK (P < 0.0083).

Conclusion: IDES can be used as a new imaging biomarker that suggests a potential risk for development of BK in patients with shallow anterior chamber who are to undergo cataract surgery.

目的:在镜面显微镜下,细胞内暗内皮斑点(IDES)表明角膜内皮应激,可以作为内皮角膜移植术后内皮细胞密度(ECD)损失的成像生物标志物。本研究通过比较低ECD患者在白内障手术前使用或不使用ide来评估大疱性角膜病变(BK)发生的危险因素。方法:这项回顾性研究包括106例连续接受白内障手术的患者,术前ECD小于1000细胞/平方毫米。根据是否存在IDES将患者分为两组。回顾性回顾术前角膜中央厚度(CCT)、ECD、前房深度(ACD)、是否存在IDES、是否存在guttae、核硬化程度、术中后囊膜破裂(PCR)和白内障术后BK的发展。比较有或无ide患者的临床因素,评价白内障术后发生BK的危险因素。结果:术前平均ECD为687±124个细胞/mm2。41眼(38.7%)发生IDES。浅ACD组IDES发生率明显高于深ACD组(P = 0.033)。22只眼(20.8%)在白内障手术后发生BK。与没有BK的患者(13.9%,P = 0.03)相比,IDES与BK的发生有显著相关性(31.7%)。CCT、核硬化、PCR和IDES被确定为术后BK的重要危险因素(P结论:IDES可作为一种新的成像生物标志物,提示行白内障手术的浅前房患者发生BK的潜在风险。
{"title":"Intracellular dark endothelial spots: A new imaging biomarker for the development of bullous keratopathy after cataract surgery.","authors":"Taiyo Shijo, Yukari Yagi-Yaguchi, Osama Ibrahim, Hirotsugu Kasamatsu, Yurina Mori-Ogiwara, Daisuke Tomida, Hisashi Noma, Dogru Murat, Takefumi Yamaguchi","doi":"10.1007/s00417-025-06846-1","DOIUrl":"10.1007/s00417-025-06846-1","url":null,"abstract":"<p><strong>Purpose: </strong>Intracellular dark endothelial spots (IDES) on specular microscopy indicate corneal endothelial stress, and can be an imaging biomarker for subsequent endothelial cell density (ECD) loss after endothelial keratoplasty. This study evaluated the risk factors for the development of bullous keratopathy (BK) by comparing low ECD patients with or without IDES before cataract surgery.</p><p><strong>Methods: </strong>This retrospective study included 106 consecutive patients who underwent cataract surgery with a preoperative ECD of less than 1000 cells/mm<sup>2</sup>. The patients were divided into 2 groups according to presence of IDES. The medical charts were retrospectively reviewed for preoperative central corneal thickness (CCT), ECD, anterior chamber depth (ACD), presence of IDES, presence of guttae, grade of nuclear sclerosis, intraoperative posterior capsule rupture (PCR) and development of BK after cataract surgery. The clinical factors were compared in patients with or without IDES and the risk factors for BK after cataract surgery were evaluated.</p><p><strong>Results: </strong>The mean preoperative ECD was 687 ± 124 cells/mm<sup>2</sup>. IDES were observed in 41 eyes (38.7%). IDES were significantly more common in eyes with shallow ACD than in those with deep ACD (P = 0.033). Twenty-two eyes (20.8%) developed BK after cataract surgery. IDES were significantly associated with the development of BK (31.7%) compared to those without BK (13.9%, P = 0.03). CCT, nuclear sclerosis, PCR, and IDES were identified as significant risk factors for postoperative BK (P < 0.0083).</p><p><strong>Conclusion: </strong>IDES can be used as a new imaging biomarker that suggests a potential risk for development of BK in patients with shallow anterior chamber who are to undergo cataract surgery.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2585-2592"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retinal oximetry: new insights into ocular and systemic diseases. 视网膜血氧测定:眼部和全身疾病的新见解。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-04-21 DOI: 10.1007/s00417-025-06831-8
Weixing Zhang, Xueer Tu, Xun Wang, Duoru Lin, Dong Liu, Weiyi Lai, Andi Xu, Jingyi Wen, Haotian Lin

Retinal oximetry, which refers to the measurement of the oxygen saturation of haemoglobin in retinal blood, has emerged as a promising tool for understanding ocular and systemic diseases over the past few decades. Advances in traditional dual-wavelength measurement techniques, as well as their integration with more advanced technologies, have driven significant progress in the field. Researchers have utilised commercially available devices to explore the applications of retinal oximetry in both healthy individuals and various disease states. To provide a comprehensive overview of the current status and development trends of retinal oximetry in ophthalmology, this review analyses relevant studies on retinal oximetry, including its principles, techniques, instrumentation, and applications in healthy individuals, ocular diseases, and systemic disorders. As a biomarker, retinal oximetry provides reliable insights into the retinal and systemic microcirculation in a noninvasive, rapid, and convenient manner. It has demonstrated potential value in the measurement of standardised data and in contributing to the understanding of disease mechanisms. However, its measurement accuracy is influenced by factors such as vessel diameter, retinal pigmentation, and optical media transparency. Future advancements, including wide-field imaging technology, nonmydriatic technology, integration with blood flow measurement techniques, and artificial intelligence, are expected to further improve the accuracy and clinical application potential of retinal oximetry.

视网膜血氧仪是指测量视网膜血液中血红蛋白的氧饱和度,在过去的几十年里,它已经成为一种很有前途的工具,用于了解眼部和全身疾病。传统双波长测量技术的进步,以及它们与更先进技术的融合,推动了该领域的重大进展。研究人员利用市售设备探索视网膜血氧仪在健康个体和各种疾病状态中的应用。本文综述了视网膜血氧仪在眼科中的研究现状和发展趋势,分析了视网膜血氧仪的原理、技术、仪器及其在健康人、眼部疾病和全体性疾病中的应用。作为一种生物标志物,视网膜血氧仪以一种无创、快速、方便的方式提供了对视网膜和全身微循环的可靠洞察。它在衡量标准化数据和促进了解疾病机制方面已显示出潜在价值。然而,其测量精度受血管直径、视网膜色素沉着、光学介质透明度等因素的影响。未来的发展,包括宽视场成像技术、非散体技术、与血流测量技术的集成以及人工智能,有望进一步提高视网膜血氧仪的准确性和临床应用潜力。
{"title":"Retinal oximetry: new insights into ocular and systemic diseases.","authors":"Weixing Zhang, Xueer Tu, Xun Wang, Duoru Lin, Dong Liu, Weiyi Lai, Andi Xu, Jingyi Wen, Haotian Lin","doi":"10.1007/s00417-025-06831-8","DOIUrl":"10.1007/s00417-025-06831-8","url":null,"abstract":"<p><p>Retinal oximetry, which refers to the measurement of the oxygen saturation of haemoglobin in retinal blood, has emerged as a promising tool for understanding ocular and systemic diseases over the past few decades. Advances in traditional dual-wavelength measurement techniques, as well as their integration with more advanced technologies, have driven significant progress in the field. Researchers have utilised commercially available devices to explore the applications of retinal oximetry in both healthy individuals and various disease states. To provide a comprehensive overview of the current status and development trends of retinal oximetry in ophthalmology, this review analyses relevant studies on retinal oximetry, including its principles, techniques, instrumentation, and applications in healthy individuals, ocular diseases, and systemic disorders. As a biomarker, retinal oximetry provides reliable insights into the retinal and systemic microcirculation in a noninvasive, rapid, and convenient manner. It has demonstrated potential value in the measurement of standardised data and in contributing to the understanding of disease mechanisms. However, its measurement accuracy is influenced by factors such as vessel diameter, retinal pigmentation, and optical media transparency. Future advancements, including wide-field imaging technology, nonmydriatic technology, integration with blood flow measurement techniques, and artificial intelligence, are expected to further improve the accuracy and clinical application potential of retinal oximetry.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2101-2115"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitrectomy with macular peeling in eyes with vitreomacular interface disorders and nonexudative age-related macular degeneration. 玻璃体切除伴黄斑剥落伴玻璃体黄斑界面病变及非渗出性老年性黄斑变性。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-05-01 DOI: 10.1007/s00417-025-06848-z
Marco Pellegrini, Ginevra Giovanna Adamo, Chiara Vivarelli, Laura Sarti, Pietro Maria Talli, Francesco Nasini, Francesco Parmeggiani, Marco Mura

Background: The aim of the study was to assess the outcomes of pars plana vitrectomy and macular peeling for vitreomacular interface disorders in eyes with coexisting nonexudative age-related macular degeneration (AMD), and to compare the rate of AMD progression in operated and fellow eyes.

Methods: This retrospective comparative study included patients with bilateral nonexudative AMD and unilateral vitreomacular interface disorder who underwent pars plana vitrectomy with internal limiting membrane peeling. Controlateral unoperated eyes were used as a control group. Cox proportional hazards regression analysis was used to compare the incidence of macular neovascularization, geographic atrophy and progression to late AMD in operated eyes and fellow eyes.

Results: 142 eyes of 71 patients were included. The mean follow-up duration was 17.5 ± 15.5 months. Best corrected visual acuity significantly improved in operated eyes (from 0.47 ± 0.25 to 0.21 ± 0.18 logMAR; p < 0.001), while no significant difference was observed in fellow eyes (from 0.18 ± 0.22 to 0.33 ± 0.56 logMAR; p = 0.055). Central retinal thickness improved in operated eyes (from 0402.9 ± 79.9 to 296.1 ± 48.4 µm; p < 0.001), while no change in fellow eyes was observed (from 296.1 ± 48.4 to 312.7 ± 110.6 µm; p = 0.205). Vitrectomy was not associated with the risk of developing macular neovascularization (hazard ratio [HR] = 0.30; 95% confidence intervals (CI) = 0.08-1.09; p = 0.068); geographic atrophy (HR = 1.01, 95% CI = 0.32-3.12; p = 0.990) nor progression to late AMD (HR = 0.64, 95% CI = 0.28-1.49; p = 0.307).

Conclusions: Pars plana vitrectomy with macular peeling for vitreomacular interface disorders in eyes with coexisting nonexudative AMD is associated with positive visual and functional outcomes, with no shot-term increased risk of AMD progression.

背景:本研究的目的是评估玻璃体切除和黄斑剥落治疗合并非渗出性老年性黄斑变性(AMD)的玻璃体黄斑界面疾病的结果,并比较手术眼和正常眼的AMD进展率。方法:回顾性比较研究双侧非渗出性黄斑变性合并单侧玻璃体黄斑界面病变行玻璃体切除合并内限制膜剥离的患者。以未手术对照眼为对照组。采用Cox比例风险回归分析比较手术眼与正常眼黄斑新生血管、地域性萎缩及进展为晚期黄斑变性的发生率。结果:纳入71例患者142只眼。平均随访时间17.5±15.5个月。手术眼最佳矫正视力显著提高(从0.47±0.25到0.21±0.18 logMAR;结论:对于合并非渗出性黄斑变性的眼,玻璃体切除合并黄斑剥落治疗玻璃体黄斑界面疾病与积极的视力和功能结果相关,短期内没有增加黄斑变性进展的风险。
{"title":"Vitrectomy with macular peeling in eyes with vitreomacular interface disorders and nonexudative age-related macular degeneration.","authors":"Marco Pellegrini, Ginevra Giovanna Adamo, Chiara Vivarelli, Laura Sarti, Pietro Maria Talli, Francesco Nasini, Francesco Parmeggiani, Marco Mura","doi":"10.1007/s00417-025-06848-z","DOIUrl":"10.1007/s00417-025-06848-z","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to assess the outcomes of pars plana vitrectomy and macular peeling for vitreomacular interface disorders in eyes with coexisting nonexudative age-related macular degeneration (AMD), and to compare the rate of AMD progression in operated and fellow eyes.</p><p><strong>Methods: </strong>This retrospective comparative study included patients with bilateral nonexudative AMD and unilateral vitreomacular interface disorder who underwent pars plana vitrectomy with internal limiting membrane peeling. Controlateral unoperated eyes were used as a control group. Cox proportional hazards regression analysis was used to compare the incidence of macular neovascularization, geographic atrophy and progression to late AMD in operated eyes and fellow eyes.</p><p><strong>Results: </strong>142 eyes of 71 patients were included. The mean follow-up duration was 17.5 ± 15.5 months. Best corrected visual acuity significantly improved in operated eyes (from 0.47 ± 0.25 to 0.21 ± 0.18 logMAR; p < 0.001), while no significant difference was observed in fellow eyes (from 0.18 ± 0.22 to 0.33 ± 0.56 logMAR; p = 0.055). Central retinal thickness improved in operated eyes (from 0402.9 ± 79.9 to 296.1 ± 48.4 µm; p < 0.001), while no change in fellow eyes was observed (from 296.1 ± 48.4 to 312.7 ± 110.6 µm; p = 0.205). Vitrectomy was not associated with the risk of developing macular neovascularization (hazard ratio [HR] = 0.30; 95% confidence intervals (CI) = 0.08-1.09; p = 0.068); geographic atrophy (HR = 1.01, 95% CI = 0.32-3.12; p = 0.990) nor progression to late AMD (HR = 0.64, 95% CI = 0.28-1.49; p = 0.307).</p><p><strong>Conclusions: </strong>Pars plana vitrectomy with macular peeling for vitreomacular interface disorders in eyes with coexisting nonexudative AMD is associated with positive visual and functional outcomes, with no shot-term increased risk of AMD progression.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2203-2208"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-year functional and structural results of faricimab for treatment-naïve neovascular age related macular degeneration: An OCT angiography study. faricimab治疗treatment-naïve新生血管年龄相关性黄斑变性的一年功能和结构结果:OCT血管造影研究。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-05-06 DOI: 10.1007/s00417-025-06849-y
Alessandra Scampoli, Matteo Mario Carlà, Giulia Grieco, Lorenzo Governatori, Roberta Catalani, Stanislao Rizzo, Tomaso Caporossi

Purpose: To explore the 1-year functional and anatomic outcomes of treatment-naïve neovascular age-related macular degeneration (nAMD) eyes undergoing a treat and extend (TAE) regimen with faricimab, METHODS: Prospective interventional study on 33 eyes with treatment-naïve nAMD undergoing a loading phase of 4 monthly faricimab followed by a TAE regimen. Participants underwent functional assessment and retinal imaging with optical coherence tomography and angiography (OCT/OCTA), at baseline and follow-up visits (V0-V5). Primary outcomes were safety, changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST). Secondary outcomes included changes in OCT biomarkers (intraretinal and subretinal fluid [IRF and SRF], maximum pigment epithelium detachment [PED] height) and vascular densities (VD) in the superficial (SCP) and deep capillary plexuses (DCP).

Results: Mean follow-up was 14.1 ± 2.7 months. At the final visit, 36.4% eyes were on a q16w regimen, and 36.4% on q12w. Results showed significant reductions in CST (V0: 334 ± 102 μm, V5: 227 ± 47 μm, p < 0.001), presence of IRF/SRF and PED height. BCVA improved significantly from 0.51 ± 0.23 to 0.36 ± 0.26 LogMAR (p = 0.03). A dry macula after the loading phase was achieved in 63.7% of cases and correlated with longer inter-injections intervals during TAE. SCP's VD showed a transient decrease in V1-V3 but returned to baseline values at V5, while no significant changes were observed in DCP VD. No cases of intraocular inflammation or adverse events were observed.

Conclusion: Faricimab showed favorable results in treatment-naive nAMD, leading to structural and functional improvements and allowing for extended treatment intervals even in real-world setting.

目的:探讨treatment-naïve新生血管性年龄相关性黄斑变性(nAMD)眼接受法利西单抗治疗和延长(TAE)方案的1年功能和解剖结果。方法:对33只treatment-naïve血管性黄斑变性(nAMD)眼进行前瞻性介入研究,进行4个月法利西单抗负荷期,然后进行TAE方案。参与者在基线和随访(V0-V5)时进行了功能评估和视网膜成像,包括光学相干断层扫描和血管造影(OCT/OCTA)。主要结果是安全性、最佳矫正视力(BCVA)的变化和中心亚视野厚度(CST)。次要结果包括OCT生物标志物(视网膜内和视网膜下液[IRF和SRF],最大色素上皮脱离[PED]高度)和浅表(SCP)和深毛细血管丛(DCP)血管密度(VD)的变化。结果:平均随访14.1±2.7个月。在最后一次访问时,36.4%的眼睛在q16周,36.4%的眼睛在q12周。结果显示CST显著降低(V0: 334±102 μm, V5: 227±47 μm, p)。结论:Faricimab在治疗初期的nAMD中显示出良好的效果,导致结构和功能改善,并允许延长治疗间隔,即使在现实环境中也是如此。
{"title":"One-year functional and structural results of faricimab for treatment-naïve neovascular age related macular degeneration: An OCT angiography study.","authors":"Alessandra Scampoli, Matteo Mario Carlà, Giulia Grieco, Lorenzo Governatori, Roberta Catalani, Stanislao Rizzo, Tomaso Caporossi","doi":"10.1007/s00417-025-06849-y","DOIUrl":"10.1007/s00417-025-06849-y","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the 1-year functional and anatomic outcomes of treatment-naïve neovascular age-related macular degeneration (nAMD) eyes undergoing a treat and extend (TAE) regimen with faricimab, METHODS: Prospective interventional study on 33 eyes with treatment-naïve nAMD undergoing a loading phase of 4 monthly faricimab followed by a TAE regimen. Participants underwent functional assessment and retinal imaging with optical coherence tomography and angiography (OCT/OCTA), at baseline and follow-up visits (V0-V5). Primary outcomes were safety, changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST). Secondary outcomes included changes in OCT biomarkers (intraretinal and subretinal fluid [IRF and SRF], maximum pigment epithelium detachment [PED] height) and vascular densities (VD) in the superficial (SCP) and deep capillary plexuses (DCP).</p><p><strong>Results: </strong>Mean follow-up was 14.1 ± 2.7 months. At the final visit, 36.4% eyes were on a q16w regimen, and 36.4% on q12w. Results showed significant reductions in CST (V0: 334 ± 102 μm, V5: 227 ± 47 μm, p < 0.001), presence of IRF/SRF and PED height. BCVA improved significantly from 0.51 ± 0.23 to 0.36 ± 0.26 LogMAR (p = 0.03). A dry macula after the loading phase was achieved in 63.7% of cases and correlated with longer inter-injections intervals during TAE. SCP's VD showed a transient decrease in V1-V3 but returned to baseline values at V5, while no significant changes were observed in DCP VD. No cases of intraocular inflammation or adverse events were observed.</p><p><strong>Conclusion: </strong>Faricimab showed favorable results in treatment-naive nAMD, leading to structural and functional improvements and allowing for extended treatment intervals even in real-world setting.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2219-2226"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic atrophy in Asia. 亚洲的地理萎缩。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-04-16 DOI: 10.1007/s00417-025-06817-6
Chui Ming Gemmy Cheung, Youxin Chen, Frank G Holz, Akitaka Tsujikawa, SriniVas Sadda

Purpose: Geographic atrophy (GA) is a late-stage manifestation of age-related macular degeneration associated with vision loss. Differences between Asian and non-Asian populations with GA have been reported. It is essential to understand these differences because they may reflect variations in the natural history of the disease and its underlying pathophysiology, impacting resultant future treatment strategies and clinical trial designs.

Methods: A non-systematic search for articles published up to November 22, 2023 was performed using PubMed. Reference lists from included articles were reviewed and relevant articles manually selected and included, as well as read for background information about the topic. Only articles in English were considered for inclusion in this narrative review.

Results: Although the overall prevalence of GA appears to be low across Asia and shows a male predominance, regional variability is evident. Compared with White and other non-Asian populations, Asian populations typically have more distinct but fewer drusen overall (regardless of type), smaller GA lesion size at presentation, a thicker choroid, and lower rates of bilaterality. In both Asian and non-Asian populations, certain characteristics of GA may be associated with an increased risk of fast disease progression.

Conclusion: The characteristics of GA in Asian populations show some similarities as well as relevant differences compared with those in White and other non-Asian populations. A better understanding of the characteristics associated with GA subphenotypes and predictors of progression will help to optimize management strategies for Asian patients with GA and improve study designs for future interventional trials.

目的:地理萎缩(GA)是与视力丧失相关的老年性黄斑变性的一种晚期表现。亚洲和非亚洲人群GA的差异已有报道。了解这些差异是至关重要的,因为它们可能反映了疾病的自然史及其潜在病理生理学的变化,从而影响未来的治疗策略和临床试验设计。方法:使用PubMed对截至2023年11月22日发表的文章进行非系统检索。我们审查了所收录文章的参考文献列表,并手动选择和收录了相关文章,并阅读了有关该主题的背景信息。只有英文文章被考虑纳入这篇叙述性评论。结果:虽然GA的总体患病率在亚洲似乎较低,并显示出男性优势,但区域差异是明显的。与白人和其他非亚洲人群相比,亚洲人群通常有更明显但更少的结节(无论类型),GA病变体积更小,脉络膜更厚,双侧发生率更低。在亚洲和非亚洲人群中,GA的某些特征可能与疾病快速进展的风险增加有关。结论:与白人及其他非亚洲人群相比,亚洲人群GA特征既有相似之处,也有相关差异。更好地了解与GA亚表型相关的特征和进展预测因素将有助于优化亚洲GA患者的管理策略,并改善未来干预性试验的研究设计。
{"title":"Geographic atrophy in Asia.","authors":"Chui Ming Gemmy Cheung, Youxin Chen, Frank G Holz, Akitaka Tsujikawa, SriniVas Sadda","doi":"10.1007/s00417-025-06817-6","DOIUrl":"10.1007/s00417-025-06817-6","url":null,"abstract":"<p><strong>Purpose: </strong>Geographic atrophy (GA) is a late-stage manifestation of age-related macular degeneration associated with vision loss. Differences between Asian and non-Asian populations with GA have been reported. It is essential to understand these differences because they may reflect variations in the natural history of the disease and its underlying pathophysiology, impacting resultant future treatment strategies and clinical trial designs.</p><p><strong>Methods: </strong>A non-systematic search for articles published up to November 22, 2023 was performed using PubMed. Reference lists from included articles were reviewed and relevant articles manually selected and included, as well as read for background information about the topic. Only articles in English were considered for inclusion in this narrative review.</p><p><strong>Results: </strong>Although the overall prevalence of GA appears to be low across Asia and shows a male predominance, regional variability is evident. Compared with White and other non-Asian populations, Asian populations typically have more distinct but fewer drusen overall (regardless of type), smaller GA lesion size at presentation, a thicker choroid, and lower rates of bilaterality. In both Asian and non-Asian populations, certain characteristics of GA may be associated with an increased risk of fast disease progression.</p><p><strong>Conclusion: </strong>The characteristics of GA in Asian populations show some similarities as well as relevant differences compared with those in White and other non-Asian populations. A better understanding of the characteristics associated with GA subphenotypes and predictors of progression will help to optimize management strategies for Asian patients with GA and improve study designs for future interventional trials.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2081-2099"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroadaptation to multifocal intraocular lenses: preliminary observations of a cognitive influence. 多焦人工晶状体的神经适应性:认知影响的初步观察。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-04-26 DOI: 10.1007/s00417-025-06832-7
Victoria S Pelak, Michael Taravella, Nathan C Grove, Jennifer L Patnaik
{"title":"Neuroadaptation to multifocal intraocular lenses: preliminary observations of a cognitive influence.","authors":"Victoria S Pelak, Michael Taravella, Nathan C Grove, Jennifer L Patnaik","doi":"10.1007/s00417-025-06832-7","DOIUrl":"10.1007/s00417-025-06832-7","url":null,"abstract":"","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2399-2401"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience. teprotumumab治疗甲状腺眼病后的改善时间:真实世界的经验。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-05-14 DOI: 10.1007/s00417-025-06855-0
Yael Lustig-Barzelay, Daniel Yagoda, Eran Zunz, Shirin Hamed-Azzam, Inbal Avisar, Shay Kehat-Ophir, Zvi Gur, Tali Cukierman-Yaffe, Nancy Agmon-Levin, Daphna Landau-Prat, Guy J Ben-Simon

Background: Teprotumumab is the only FDA-approved medication for thyroid eye disease (TED), showing benefits in reducing proptosis, diplopia, clinical activity score (CAS), and improving quality of life. This study describes the clinical outcomes of TED patients treated with Teprotumumab across 5 medical centers in Israel and evaluates time-to-improvement.

Methods: A retrospective cohort study of electronic medical records for Israeli patients treated with Teprotumumab between 2021 and 2024 in five medical centers. The main outcome included changes in proptosis and diplopia.

Results: Thirty-two TED patients (mean age 53.3, 19 females) received partial or complete treatment with Teprotumumab. All had previously failed IV glucocorticoids, and some also failed other biologics. Four patients had decompression surgery prior; 3 with optic neuropathy and 1 with proptosis improved after 1-7 doses. Proptosis decreased by 2.4mm (right) and 2.0mm (left) (p < 0.001, p = 0.002, paired sample t-test), with significant reductions in primary gaze diplopia (p = 0.015, chi-square test). Four patients (12.5%) had symptom recurrence 8-12 months post-treatment; one improved with additional treatment. Thirteen patients (40.6%) had significant improvement within 3 infusions. Adverse events included myalgia (n = 4), hyperglycemia (n = 3), diarrhea (n = 3), and hearing issues (n = 4). One patient developed encephalopathy, successfully treated with plasmapheresis.

Conclusions: Teprotumumab was effective in reducing diplopia and proptosis among Israeli TED patients, with rapid improvement in nearly half of the cases. Further studies are warranted to confirm these findings in real-world settings.

背景:Teprotumumab是fda批准的唯一治疗甲状腺眼病(TED)的药物,在减少眼球突出、复视、临床活动评分(CAS)和改善生活质量方面显示出益处。本研究描述了以色列5个医疗中心接受Teprotumumab治疗的TED患者的临床结果,并评估了改善时间。方法:对5个医疗中心2021年至2024年间接受Teprotumumab治疗的以色列患者的电子病历进行回顾性队列研究。主要观察结果包括视力和复视的改变。结果:32例TED患者(平均年龄53.3岁,19例女性)接受了Teprotumumab的部分或完全治疗。所有患者先前都曾静脉注射糖皮质激素失败,其中一些人也曾服用其他生物药物失败。4例患者既往行减压手术;1 ~ 7次用药后,视神经病变3例,眼球突出1例好转。结论:Teprotumumab可有效降低以色列TED患者的复视和眼球突出,近一半的病例有快速改善。进一步的研究需要在现实环境中证实这些发现。
{"title":"Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.","authors":"Yael Lustig-Barzelay, Daniel Yagoda, Eran Zunz, Shirin Hamed-Azzam, Inbal Avisar, Shay Kehat-Ophir, Zvi Gur, Tali Cukierman-Yaffe, Nancy Agmon-Levin, Daphna Landau-Prat, Guy J Ben-Simon","doi":"10.1007/s00417-025-06855-0","DOIUrl":"10.1007/s00417-025-06855-0","url":null,"abstract":"<p><strong>Background: </strong>Teprotumumab is the only FDA-approved medication for thyroid eye disease (TED), showing benefits in reducing proptosis, diplopia, clinical activity score (CAS), and improving quality of life. This study describes the clinical outcomes of TED patients treated with Teprotumumab across 5 medical centers in Israel and evaluates time-to-improvement.</p><p><strong>Methods: </strong>A retrospective cohort study of electronic medical records for Israeli patients treated with Teprotumumab between 2021 and 2024 in five medical centers. The main outcome included changes in proptosis and diplopia.</p><p><strong>Results: </strong>Thirty-two TED patients (mean age 53.3, 19 females) received partial or complete treatment with Teprotumumab. All had previously failed IV glucocorticoids, and some also failed other biologics. Four patients had decompression surgery prior; 3 with optic neuropathy and 1 with proptosis improved after 1-7 doses. Proptosis decreased by 2.4mm (right) and 2.0mm (left) (p < 0.001, p = 0.002, paired sample t-test), with significant reductions in primary gaze diplopia (p = 0.015, chi-square test). Four patients (12.5%) had symptom recurrence 8-12 months post-treatment; one improved with additional treatment. Thirteen patients (40.6%) had significant improvement within 3 infusions. Adverse events included myalgia (n = 4), hyperglycemia (n = 3), diarrhea (n = 3), and hearing issues (n = 4). One patient developed encephalopathy, successfully treated with plasmapheresis.</p><p><strong>Conclusions: </strong>Teprotumumab was effective in reducing diplopia and proptosis among Israeli TED patients, with rapid improvement in nearly half of the cases. Further studies are warranted to confirm these findings in real-world settings.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2349-2358"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interocular distribution differences of parafoveal cone photoreceptors between dominant and non-dominant eyes assessed using an adaptive optics scanning laser ophthalmoscope. 应用自适应光学扫描激光检眼镜评估优势眼与非优势眼的眼内分布差异。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-05-10 DOI: 10.1007/s00417-025-06852-3
Ying Chen, Huiling Ma, Huiyan Li, Xinyun Wang, Menghui Zhang, Sisi Liu, Xiawei Wang, Hongguang Cui

Purpose: To investigate distribution differences of parafoveal cone photoreceptors between dominant and non-dominant eyes using the adaptive optics scanning laser ophthalmoscope (AO-SLO) system.

Methods: This retrospective study included 156 eyes from 78 healthy subjects, all of whom had best-corrected visual acuity of 20/20 or better in both eyes and underwent ophthalmological examinations. The dominant eye was determined using the hole-in-the-card test. Retinal cone photoreceptor observations were performed at an eccentricity of 3.0° from the foveal center using the AO-SLO system. Quantitative distribution parameters, including cone density, spacing, regularity, and dispersion of both dominant and non-dominant eyes, were analyzed and compared.

Results: Dominant eyes exhibited higher cone photoreceptors density at a 3.0° horizontal eccentricity from the fovea [22,896 (20,954, 25,179) cells/mm2] than non-dominant eyes [22,621 (20,147, 24,253) cells/mm2] (p = 0.03). Correspondingly, the spacing of cone photoreceptors in dominant eyes [5.41 (5.09, 5.68) µm] was smaller than that in non-dominant eyes [5.47 (5.23, 5.72) µm] (p = 0.041). The interocular difference in cone regularity between dominant [96.53 (95.07, 97.46)%] and non-dominant [96.68 (95.49, 97.57)%] eyes was statistically significant (p = 0.04). However, there was no significant interocular difference in cone dispersion, which could reflect distribution uniformity (p = 0.795).

Conclusion: Our findings reveal that the dominant eye exhibits higher cone density in the parafoveal region with narrower spacing but a less regular arrangement than the non-dominant eye. These cytological features provide new evidence linking cone photoreceptor distribution to ocular dominance, which may account for the electrophysiological asymmetry observed between the two eyes.

Key messages: What is known? • The adaptive optics scanning laser ophthalmoscope can correct aberrations caused by irregularities in the eye's optics, allowing for the direct and noninvasive observation of retinal microstructures in vivo. What is new? • Our study reveals that parafoveal cone photoreceptors in dominant eyes exhibit significantly higher density, narrower spacing, and a less regular arrangement compared to those in non-dominant eyes in vivo. • The cytological asymmetry between photoreceptor cells in dominant and non-dominant eyes may serve as a potential basis for the electrophysiological differences observed between the two.

目的:应用自适应光学扫描激光检眼镜(AO-SLO)系统研究优势眼和非优势眼的中央凹锥体光感受器分布差异。方法:本回顾性研究纳入78名健康受试者的156只眼,所有受试者双眼最佳矫正视力均在20/20及以上,并接受眼科检查。主视眼是通过卡片穿洞测试确定的。采用AO-SLO系统在距中央凹中心3.0°偏心位置观察视网膜锥状体光感受器。对优势眼和非优势眼的锥体密度、间距、规律性和分散性等定量分布参数进行了分析比较。结果:优势眼在距中央凹水平偏心3.0°时,锥体光感受器密度[22,896(20,954,25,179)个细胞/mm2]高于非优势眼[22,621(20,147,24,253)个细胞/mm2] (p = 0.03)。优势眼视锥体光感受器间距[5.41(5.09,5.68)µm]小于非优势眼视锥体光感受器间距[5.47(5.23,5.72)µm] (p = 0.041)。优势眼与非优势眼视锥规则性差异有统计学意义(p = 0.04)。优势眼与非优势眼视锥规则性差异有统计学意义(p = 0.04)。但视锥色散在眼间无显著差异,可反映分布均匀性(p = 0.795)。结论:与非优势眼相比,优势眼的中央凹区锥体密度更高,间距更窄,但排列更不规则。这些细胞学特征提供了新的证据,证明视锥光感受器的分布与眼优势有关,这可能解释了在两只眼睛之间观察到的电生理不对称。关键信息:什么是已知的?•自适应光学扫描激光检眼镜可以纠正由于眼睛光学不正常引起的像差,从而实现对体内视网膜微观结构的直接无创观察。有什么新鲜事吗?•我们的研究表明,与非优势眼相比,优势眼的旁中央凹锥体光感受器在体内表现出更高的密度、更窄的间距和更不规则的排列。•显性眼和非显性眼感光细胞之间的细胞学不对称可能是两者之间观察到的电生理差异的潜在基础。
{"title":"Interocular distribution differences of parafoveal cone photoreceptors between dominant and non-dominant eyes assessed using an adaptive optics scanning laser ophthalmoscope.","authors":"Ying Chen, Huiling Ma, Huiyan Li, Xinyun Wang, Menghui Zhang, Sisi Liu, Xiawei Wang, Hongguang Cui","doi":"10.1007/s00417-025-06852-3","DOIUrl":"10.1007/s00417-025-06852-3","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate distribution differences of parafoveal cone photoreceptors between dominant and non-dominant eyes using the adaptive optics scanning laser ophthalmoscope (AO-SLO) system.</p><p><strong>Methods: </strong>This retrospective study included 156 eyes from 78 healthy subjects, all of whom had best-corrected visual acuity of 20/20 or better in both eyes and underwent ophthalmological examinations. The dominant eye was determined using the hole-in-the-card test. Retinal cone photoreceptor observations were performed at an eccentricity of 3.0° from the foveal center using the AO-SLO system. Quantitative distribution parameters, including cone density, spacing, regularity, and dispersion of both dominant and non-dominant eyes, were analyzed and compared.</p><p><strong>Results: </strong>Dominant eyes exhibited higher cone photoreceptors density at a 3.0° horizontal eccentricity from the fovea [22,896 (20,954, 25,179) cells/mm<sup>2</sup>] than non-dominant eyes [22,621 (20,147, 24,253) cells/mm<sup>2</sup>] (p = 0.03). Correspondingly, the spacing of cone photoreceptors in dominant eyes [5.41 (5.09, 5.68) µm] was smaller than that in non-dominant eyes [5.47 (5.23, 5.72) µm] (p = 0.041). The interocular difference in cone regularity between dominant [96.53 (95.07, 97.46)%] and non-dominant [96.68 (95.49, 97.57)%] eyes was statistically significant (p = 0.04). However, there was no significant interocular difference in cone dispersion, which could reflect distribution uniformity (p = 0.795).</p><p><strong>Conclusion: </strong>Our findings reveal that the dominant eye exhibits higher cone density in the parafoveal region with narrower spacing but a less regular arrangement than the non-dominant eye. These cytological features provide new evidence linking cone photoreceptor distribution to ocular dominance, which may account for the electrophysiological asymmetry observed between the two eyes.</p><p><strong>Key messages: </strong>What is known? • The adaptive optics scanning laser ophthalmoscope can correct aberrations caused by irregularities in the eye's optics, allowing for the direct and noninvasive observation of retinal microstructures in vivo. What is new? • Our study reveals that parafoveal cone photoreceptors in dominant eyes exhibit significantly higher density, narrower spacing, and a less regular arrangement compared to those in non-dominant eyes in vivo. • The cytological asymmetry between photoreceptor cells in dominant and non-dominant eyes may serve as a potential basis for the electrophysiological differences observed between the two.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2389-2397"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bezafibrate was unsuccessful to treat leber hereditary optic neuropathy. 贝扎布特治疗leber遗传性视神经病变不成功。
IF 2.4 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2025-08-01 Epub Date: 2025-05-16 DOI: 10.1007/s00417-025-06835-4
Christophe Orssaud
{"title":"Bezafibrate was unsuccessful to treat leber hereditary optic neuropathy.","authors":"Christophe Orssaud","doi":"10.1007/s00417-025-06835-4","DOIUrl":"10.1007/s00417-025-06835-4","url":null,"abstract":"","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":"2403-2405"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Graefe’s Archive for Clinical and Experimental Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1